1. Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial. Issue 3 (March 2023) Authors: Laffel, Lori M; Danne, Thomas; Klingensmith, Georgeanna J; Tamborlane, William V; Willi, Steven; Zeitler, Philip; Neubacher, Dietmar; Marquard, Jan; Bardymova, Tatiana; Barrientos Perez, Margarita; Bethin, Kathleen; Bjornstad, Petter; Bondar, Irina; Chen, Mimi; Choi, Jin-Ho; Clements, Mark A; Col... Journal: Lancet Issue: Volume 11:Issue 3(2023) Page Start: 169 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗